ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: King ACCC President, Fleming President Elect; Wyngaarden Says He Doesn’t Oppose Panel

March 25, 1988

NCI Plans 3 Percent Across-The-Board Cut To Pool Funds For High Priorities In FY08.

September 21, 2007

In Brief: NCI May Support Studies Of Heat As Therapeutic Method DTIC OK Near for Malignant Melanoma

May 16, 1975

Where’s The Money for Local Programs? Everyone Wants To Know

February 28, 1975

Guest Editorial: Group Chairs Urge Implementation of NCI plan. Next Step: Bioinformatics and Tissue Banks

November 11, 2011

Radioactive Seeds Tested In Treatment Of NSCLC

September 26, 2008